Interviews with Key Opinion Leaders (KOLs) from Across the Stem Cell Industry

BioInformant's Founder, Cade Hildreth, has interviewed hundreds of key opinion leaders (KOL's) from across the stem cell industry.

Regenerative Outcomes, LLC, Achieves Rapid Growth, as Demand for RMAT Consultancy Expands – Interview with Megan Moneypenny, CEO

May 1, 2019 By Cade Hildreth (CEO) Leave a Comment

I am honored to release this interview with Megan Moneypenny, CEO of Regenerative Outcomes, LLC, a rapidly growing consulting firm within the emerging field of Regenerative Medicine, with a specialty in RMAT consulting. Regenerative Outcomes is an organization that was spun out from the Regenerative Outcomes Foundation, a non-profit group founded by Doug Oliver. Doug has an incredible story of being a stem cell patient, turned renowned advocate and consultant within the field of regenerative medicine. [Read more…]

L7 Informatics, Data Management and Process Automation Solutions for Cell and Gene Therapy Companies

April 22, 2019 By Cade Hildreth (CEO)

Headquartered in Austin, Texas, L7 Informatics, provides software and services that enable synchronized solutions for cell and gene therapy companies. Specifically, L7’s novel Enterprise Science Platform (ESP) is a scientific process and data management (SPDM) solution that enables life science and healthcare companies to connect people, processes, and systems. The company’s mission is to use this technology to accelerate discoveries and drive precision healthcare.

In this interview, Vasu Rangadass – President and CEO of L7 Informatics – and I explore the company’s origins, its unique ESP technology, future directions, and more. Enjoy! [Read more…]

“Vision For The Future” Takes On New Meaning As Doug Oliver, Founder of The Regenerative Outcomes Foundation, Shares What Lies Ahead In His Journey

April 9, 2019 By Cade Hildreth (CEO)

I am honored to release this interview with Doug Oliver, Founder of the Regenerative Outcomes Foundation. Doug has an incredible story of being a stem cell patient, turned renowned advocate and consultant within the field of regenerative medicine. In this interview, we explore what inspired him to establish the Regenerative Outcomes Foundation, his awards and accolades within the field, the critical importance of advocacy work, and so much more. Enjoy! [Read more…]

Rhemastem, Leveraging Stem Cells from Solid Tumors in the Race to Cure Colorectal Cancer

April 1, 2019 By Cade Hildreth (CEO)

Headquartered in Monza, Italy, RhemaStem is a unique biotech company that specializes in developing innovative and effective drugs for colorectal cancer and other solid cancers. The company’s mission is to cure colorectal cancer and other solid cancers using its expertise in the area of cancer and normal stem cells. I had the distinct honour of interviewing Dr. Zeni of RhemaStem.

In this interview, we explore the founding of Rhemstem, its unique technology platform, intellectual property (IP), future directions, and more. Enjoy! [Read more…]

Breakthrough Solutions for Human Primary Cells & Hematologic Tissue Products

March 24, 2019 By Cade Hildreth (CEO)

AllCells is a biotechnology company that specializes in biologically relevant, high quality primary cells to enable drug discovery, development, and manufacturing of cell therapies. Leveraging its expertise in hematological and immune cell isolations, combined with on-site whole blood and bone marrow tissue collection operations, AllCells maintains one of the world’s largest and most diverse repositories of donor profiles that can be screened and qualified for biomedical applications.

I had the honor of interviewing Dr. Jay Tong, President and CEO of AllCells. In this interview, we discuss AllCells history, its leadership in blood donor cell collections and hematologic tissue products and the recent opening of its newest facility in Boston, Massachusetts. We also explore the company’s long-term goals and expansion into the cell therapy development space. [Read more…]